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Interpretation of Short-Term Test Data
by David Brusick*
Thegenetictoxicology datas for chemicalsthathavebeentestedextensively aregenerafly composedofinconsis-
tent responsesfrom adiversesetofassays Consequently, difiultiesarise whenthedata areevWaluatedforcassfyingthe
agent orfor a ng thechemical'shazard . Several years ago, theInternational Co iion forProtection
apinstEnvironmentalMutagensandCardnogens (ICPEMC) b d a committeetoconsdruct a processfor com-
pilingand inte tingdiversedatasetl TbeCommittee as delopedaeight-of-evidenceapROChthatcombinestest
data into a series of scores for test type, class, faly, and a s coredeffing the relative mutagenic vity of the
agentcomparedwithother chemcasinthedatab Thisreportdescribesthemethodandpreliminaryresultsfrom113
chemicals.
Introduction
Committee 1 ofTheInternationalCommissionforProtection
againstEnvironmental Mutagens andCarcinogens (ICPEMC)
wasestablishedin L979toreviewthestatusofshort-termtestsfor
mutagenicity andthedegree towhichthesetests areconcordant
withresultsfrom three mammaLianin wvotests(dominantletal,
heritabletranslocation, andspecific locus) measuring germ cell
damage(1). The missionofcommittee 1 wasbroadenedin 1983
todevelop, ifpossible, amethodthatwouldintegrateandinter-
pretresults fromheterogeneousdatatypicalofmutagenicity test
batteries.
Committee 1 members began with a weight-of-evidence
scheme proposed by Brusick (2). This system was based on a
methodofweighted averages ofbothpositiveandnegative test
results from abattery consisting ofboth in vitro and submam-
malian assays. Allthoughthecommittee retainedtheweight-of-
evidence portion of the approach, range of assays and the
mechanicsofdatahandling forthecurrentmethodhaveevolved
substantially.
There werethreeprimaryobjectivesthatcommittee 1 setout
toaccomplish inthedesignofadataanalysis method. Thefirst
goal was to develop a method that would extend the use of a
databasebeyondlisting testsandresults. Formutagenicitythere
was aneedforaprocesstoassemblethetestresultsforachemical
in a manner that would produce a consensus regarding the
mutagenic activity ofthe agent. Thesecondgoal was to usethe
resultsoftheevaluationstorankchemicalsandcomparethatrank
orderwithotherpropertiesofthe samechemicalssuch as cancer
orgermcellmutation. Thethirdgoal wasto usethedataanalysis
with alargedatabasetounderstandmutagenicity testsandtheir
relationships to each other and to chemicals and chemical
classes.
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Comparison with Other Methods
of DataAnalysis
Several other investigators have developed or proposed ap-
proachestoaccomplish manyoftheobjectivesstatedabove. One
ofthe earlier uses ofthe data in this manner was proposed by
Squire (3) in which he suggested a semiquantitative approach
that estimated carcinogenic potential using a point system for
variouscharacteristicsofachemical. Mutagenicity washighest
weightedofallcomponentsofhiscarcinogenpredictionscheme.
Inthemid-1980s, Waters etal. (4)developed alinearprofile
ofmutagenic activity that illustrated the positive and negative
results forall testsconducted on achemical (Fig. 1). Thisplot,
identified as aGenetic Activity Profile (GAP), has undergone
several improvements andis currently availablewith an exten-
sivedatabase onPC-based software (4). GAPs facilitatedirect
comparison oftest responses for chemicals ofsimilar classes
and/or structural relatedness.
Otherinvestigatorshaveattemptedtoused statistical (5) and
structure-activity analyses(6)ofshort-termtestresultstopredict
carcinogenicactivityofchemicalsandtoconstructmorereliable
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Table 1. Thecurrentfamily, class, andteststructure.'
Family: In vitro
Class Al:Primary DNAdamage-prokaryotes
BRD Other DNA repair-deficient bacteria differential toxicity
BSD Bacillussubtilis recstrains, differential toxicity
ECD Escherichia colipolA/W3110-P3478, differential toxicity (spot
test)
ECL Escherichia colipolAlW3110-P3478, differential toxicity (liquid
suspension)
ERD Escherichia coli rec strains, differential toxicity
Class A2: Primary DNAdamage-lowereukaryotes
SCG Saccharomyces cerevisiae, geneconversion
SCH S. cerevisiae, homozygosis by recombination orgeneconversion
Class A3: Primary DNAdamage-mammalian cells
UHF Unscheduled DNA synthesis, humanfibroblasts
UHL Unscheduled DNA synthesis, human lymphocytes
UHT Unscheduled DNA synthesis, transformed humancells
UIA Unscheduled DNA synthesis, otheranimal cells
UIH Unscheduled DNA synthesis, otherhumancells
URP Unscheduled DNA synthesis, ratprimary hepatocytes
Class A4: Gene mutation-prokaryotes
BSM Bacillussubtilis multigene test
EC2 Escherichia coliWP2, reverse mutation
ECF Escherichia coli(excluding strain K12), forward mutation
ECK Escherichia coliWP2UVRA, reverse mutation
ECR Escherichia coli (other miscellaneous strains), reverse mutation
SAL Salmonella typhimurium, all strains
Class A5: Genemutation-lower eukaryotes
NCF Neurospora crassa, forward mutation
NCR Neurospora crassa, reverse mutation
SCF Saccharomyces cerevisiae, forward mutation
SCR Saccharomyces cerevisiae, reverse mutation
SZF Schizosaccharomycespombe, forward mutation
Class A6: Gene mutation-mammalian cells
G51 Genemutation, mouse L5178Y, all other loci
G5T Gene mutation, mouse L5178Ycells, TKlocus
G9H Genemutation, Chinese hamsterlung V-79cell, HPRT
G90 Genemutation, Chinese hamster lung V-79cells, ouabain
GCO Genemutation, Chinese hamsterovary cells
GIA Genemutation, otheranimal cells
Class A7: Aneuploidy-lower eukaryotes
SCN Saccharomyces cerevisiae, aneuploidy
Class A8: Sisterchromatid exchange-mammalian cells
SIA Sisterchromatid exchange, otheranimal cells
SHL Sisterchromatidexchange, human lymphocytes
SHF Sisterchromatidexchange, humanfibroblasts
SIC Sisterchromatid exchange, Chinese hamstercells
SIH Sisterchromatid exchange, otherhuman cells
SIS Sisterchromatidexchange, Syrian hamstercells
SIR Sisterchromatidexchange, ratcells
SIM Sisterchromatidexchange, mousecells
SIT Sisterchromatid exchange, transformed cells
Class A9: Chromosome aberration-mammalian cells
CIA Chromosome aberrations, otheranimals cells
CHL Chromosome aberrations, human lymphocytes
CHF Chromosome aberrations, human fibroblasts
CIC Chromosomal aberrations, Chinese hamstercells
CIH Chromosomal aberrations, other humancells
CIS Chromosomal aberrations, Syrianhamstercells
CIR Chromosomal aberrations, ratcells
CIT Chromosomal aberrations, transformedcells
Class A10: Transformation-mammalian cells
T7S Celltransformation, SA7/Syrian hamsterembryo cells
T7R Celltransformation, SA7/ratcells
TBM Celltransformation, BALB/C3T3 mousecells
TCL Cell transformation, otherestablished cell lines
TCS Cell transformation, Syrian hamsterembryocells, clonal assay
TCM Celltransformation, C3HlOTl/2 mouse cells
TRR Celltransformation, RLV/Fischer ratembryocells
Family: In vivo
Class B1: DNA repair, somatic-mammal
UBH Unscheduled DNA synthesis, human bone marrowcells
UPR Unscheduled DNA synthesis, rat hepatocytes
UVA Unscheduled DNA synthesis, other animal cells
UVC Unscheduled DNA synthesis, hamstercells
UVR Unscheduled DNA synthesis, other ratcells
UVM Unscheduled DNA synthesis, mousecells
Class B2: Genemutation, somatic-insect Drosophila
DMM Drosophila melanogaster, somatic mutation (and recombination)
Class B3: Spottest, somatic-mammal
MST Mouse spottest
Class B4: Sisterchromatid exchange, somatic-mammal
SLH Sisterchromatidexchange, humanlymphocytes
SVA Sisterchromatid exchange, animal cells
SVH Sisterchromatidexchange, otherhumancells
Class B5: Micronuclei, somatic-mammal
MVC Micronucleus test, hamsters
MVM Micronucleus test, mice
MVR Micronucleus test, rats
Class B6: Chromosomeaberration, somatic-mammal
CBA Chromosomal aberrations, animal bone marrow cells
CBH Chromosomal aberrations, human bone marrow cells
CLA Chromosomal aberrations, animal leukocytes
CLH Chromosomal aberrations, humanlymphocytes
CVA Chromosomal aberrations, otheranimal cellstreated
Class B7: Heritable damage-insect, Drosphila
DMH Drosophila melanogaster, heritable translocation test
DML Drosphila melanogaster, dominant lethal test
DMX Drosophila melanogaster, sex-linked recessive lethal mutation
Class B8: Heritable specific locus-mammal
SLO Mouse specific locus test, other stages
Class B9: Dominant lethal-mammal
DLM Dominant lethal test, mice
DLR Dominant lethal test, rats
ClassB1O: Heritable translocation-mammal
MHT Mouse heritable translocation test
Class B11: Chromosome aberration, germinal-mammal
CCC Chromosomal aberrations, spermatocytes treated andobserved
CGC Chromosomal aberrations, spermatogonia treatedandobserved
CGG Chromosomal aberrations, spermatogonia treated and observed
COE Chromosomalaberrations, oocytes orembryos treated
Class B12: Spermmorphology-mammal
SPM Sperm morphology, mouse
SPR Sperm morphology, rat
SMS Spermmorphology, sheep
aCode namesaccording toWaters etal. (4). Only 85 tests are used. Critrion has beenthat inthetotal database a test had tobe used forat least fivechemicals.
bAll strains ofSalmonella included. The highest dose negative or lowestdosepositive in any oneofthe strains involved inone entry istaken.
testbatteriesfordetectingmutageniccarcinogens. Parodietal.
(7)haveproposedamethodusingseveralparameterstopredict
bothqualitatively andquantitatively thecarcinogenicactivityof
chemicals. Thesuccessofthisapproachwasfoundtobechemi-
cal-class dependent.
Thecommittee 1activitytodatehasbeendirectedtowardrank-
ingformutagenicactivity.Futureeffortsareplannedforcompar-
ing the ICPEMC mutagenicity rankings to animal carcinogen
standardssuchasthoseproposedbyGoldetal. (8). Inanactivi-
tyrelatedtothisend, Nesnow(9)constructedamultifactorrank-
ingschemeforcomparingthecarcinogenic activityofchemicals.
This scheme was produced in collaboration withcommittee 1
andusedasimilarprocesstoweightfactorsthatinfluencepoten-
cy tothe oneused inthemutagenicity ranking approach.
Each of the methods described has attributes that make it
useful forspecific purposes, butthemethods areall primarily
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FIGURE 2. The ICPEMC mutagenic activity profile for ethylene oxide. The
upperportionofthediagram gives the individual test results for in vitro and
in vivo assays. The location ofthe response on the scale (-100 to +100) in-
dicates whether the results were positive or negative. The lower portion of
the diagram gives the class (1-10), family (Sf), and agent (Sa) scores. Classes
are identified by the numbers along the X-axis.
oriented towardcarcinogenesis. GAPs are similar to the commit-
tee 1 approach inboth graphic output and inthe factthat they are
directed toward mutagenicity per se.
Data Evaluation Methods Developed
by ICPEMC
Oncethebasic structure ofthe committee 1 approach hadbeen
determined, data collection and analysis programs were written
inFORTRAN 77 for a Digital VAX 750computer. The software
program wasdesigned tobeflexibleandamenable toadjustment
(finetuning) asdataentered intothedatabase wereevaluated. An
alternateversion ofthe program is being prepared for IBM-AT
compatible personal computers. The ICPEMC approach has
been identified as the mutagenic activity profile (MAP) method
because ofthe graphic output format and because the scheme
ranks chemicals according to their activity. Details ofthe data
evaluation systemandthetechniques employed tomaximize use
ofthe method are currently in press (10,11).
In summary, the approach uses a weight-of-evidence concept
combined with unweighted averaging of modified test results.
Thequalitative test responses (positive or negative) aremodified
by two factors: dose and assay replication. Defining doses are
selected fromthe lowest effective dose (positive results) and the
highest ineffective dose (negative results). Dose modifiers,
which have been corrected for bias introduced by characteristics
associated with the test system (11), are then applied to the
calculations.
Each test system for whichdata canbeentered into thescheme
is uniquely identified by a three-letter code (Table 1) proposed
by Waters etal. (4). Trials ofindividual tests are transformed to
produce test scores. Scores from individual tests are combined
into class scores by simple unweighted averaging. Test classes
have phylogenetic and end point traits in common (e.g., gene
mutation tests in prokaryotic cells, chromosome aberrations in
culturedmammalian cells); a class such as A6 consists of tests
that arepresumed todetect genemutation inculturedmammalian
cells. Results fromthe L5178Y mouse lymphoma assay, HGPRT
assay in Chinese hamster ovary or V79 cells, or gene mutation
tests using human cell types would be combined in the A6 class.
In vivo classes were constructed in a similar fashion. For exam-
ple, class B6 consists of bone marrow metaphase cytogenetic
analysis in mice, rats, hamsters, and humans.
Merging data into classes is performed by simple averaging.
Class scores are combined into family scores, again by simple
averaging. There are two family scores, one for in vitro results
and one for in vivo results.
Figure 1 summarizes the steps in the process for assembling
and merging data into test, class, family, and agent scores. The
process determines a score for each trial of a given test and then
merges theminto a score for the test, a score for theclass, a score
for the family, and finally, a single agent score (Sa) representing
the consensus (weight-of-evidence) for the chemical. The con-
sensus score defines the overall mutagenic activity based on all
the test results.
The results of the evaluation process are expressed in both
tabular and graphic formats. The tabular output lists each of
thescores identified above, the calculations producing the scores,
and reference citations for each ofthe data entries. The graphic
format forethylene oxide (Fig. 2) is used as an example and can
be compared totheGAPgraphics in Figure 3. TheICPEMC pro-
files are presented in diagrams with upper and lower plots. The
upper portion of the diagram gives (in the two hemispheres)
modified test scores for each trial (with a mean and confidence
limits ifthe replicate number isthree or greater), along withthe
three-letter identification code. Agent scores (Sa) can theo-
retically range from -100 to +100 with the 0 separating the ac-
tive (+) or inactive (-) responses.
Ateach step ofthe process, scores areaveraged with negative
results down-weighting positive scores. Themajordeterminants
for location ofthe scores on scale are sign (+ or -), defining
dose, and replication ofthe test. Thefinalmerging represents a
consensus ofall entries. The testcodes arearranged sothatthe
i,A vdro (A) in vivo (6)
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FIGURE 3. The genetic activity profile forethyleneoxide. Tests are arranged inphylogenetic groups. Data are formatted according to the strength ofresponse in
both positive and negative directions. (Courtesy ofM. Waters.)
tests within agivenclass (e.g., Al, A2, orBi, B2) areclustered
together. The lower portion ofthe diagram provides the class
scores, family scores, and agent score. The name of the
chemical, currentdate, and CAS number forthe agent are also
provided on theplot.
Therationaleforincluding agraphic aswell astabularoutputs
area) toprovide alldatain aconvenient, informative manner on
asingle pageforquickreferenceandb)topermituserstofollow
the influence ofthedatareduction steps ontheinitial testresults.
The data analysis and merging program has continued to
evolve as more insight about testperformance anddataanalysis
hasbeengained. Consequently, therehavebeenseveralversions
ofthe agent scores, which have resulted in slight shifts ofthe
chemical ranking. The system isapproaching apointwherethe
committeebelieves thatitisworkingsufficiently wellthatfinal
settings for the modifiers can made and the system should be
released forgeneral use. Becauseofthedesignofthe program,
additional information gained during use ofthe system can be
used to "educate" the process by finetuning themodifiers orby
weighting some ofthe variables (10,12).
Indevelopingthe process inthis manner, certainassumptions
weremadeby themembers ofthe committee: a) there were no
establishedprocedures available forusingtestresults toclassify
chemicals asnonmutagens, but one wasneeded; b)there wasin-
sufficientinformationavailableto setweights fordifferenttests.
Therefore, all tests were assumed to be equally relevant to the
process ofdetermining mutagenic activity; c) bothin vitro and
in vivodata wouldberequired toprovide anaccurateassessment
ofthegenetic activityofachemical; d) replicationofthe agent
in a test (up to apoint) shouldprovide, onthe average, abetter
estimateofthemutagenicactivity forthechemical than asingle
trial; e) merging test results, especially replicates of a test and
testsmeasuringthe sameendpointinsimilartypesoforganisms,
would not significantly violate scientific principles because a
similar process is performed intuitively by most toxicologists
when evaluatingmultitest results for a chemical.
Source of Data in the Database
The currentdatabase used to evaluate the approach and per-
form the statistical analyses consists of 4490 results for 113
chemicals. Theprimary data was provided to ICPEMC by the
U.S. Environmental Protection Agency and contained results
frommanyofthechemicalsintheIARCSupplement6(13). The
chemicals intheMAPdatabaseallhaveatleastthreein vitrotests
andatleasttwoin vivo tests. Thecommittee settheseminimums
asrequirementstoevaluatetheabilityofthemethodtohandlelarge
heterogeneousdata setsandbecausemostofthetestbatteries in
common usegenerally contained both in vitro and in vivo tests.
Concerns and Limitations
ofthe Approach
The committee realized that developing a data evaluation
schemewouldinvolvetreatinggenotoxicitydatainwaysthatare
different from treatments typically used to evaluate groups
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Chemical
Ethanol
Melamine
Chlorodifluoromethane
C.I. Acid Red 14
Pentachloronitrobenzene
Saccharin
Halothane
Inoniazide
Phenylbutazone
Caprolactam
Diethylhexylphthalate
Polychlorinated biphenyls
Ethylenethiourea
Sodium saccharin
Methoxychlor
Polybrominated biphenyls
Chloroform
Chloramphenicol
Metronidazole
Maleic hydrazide
1,1,l-Trichloroethane
Dichloromethane
Tetrachloroethylene
Phenobarbital
Endrin
Mestranol
Progesterone
Tetraethylthiurum disulfide
Malathion
Amitrole
N-Nitrosodiphenylamine
Aniline
Lead
Chrysene
Asbestos
Benzene
Caffeine
Sodium fluoride
Cyclohexylamine
Heptachlor
Diazepam
DDT
Carbon tetrachloride
Methyl parathion
Dieldrin
Phenytoin
o-Toluidine
Trichloroethylene
Benz(a)anthracene
Styrene
Hexachlorocyclohexane
Pentachlorophenol
Dimethoate
5-Fluorouracil
Table2. Agentscores for 113chemicals inthedatabase.
Score Chemical
-27.70 Vinyl chloride
-26.38 Acrylonitrile
-26.05 p-Nitro-o-phenylenediamin
-23.26 Diethylstilbestrol
-20.45 Malonaldehyde
-18.78 2,3,7,8-TCDD
-18.69 I-Naphthylamine
-18.59 Vinylidenechloride
-18.39 Auramine
-18.21 Cadmium
-17.35 Methotrexate
-16.88 2,4-D
-16.77 MCPA
-15.76 Aldrin
-15.71 Procarbazine HCI
-15.46 Benzyl chloride
-15.28 Dimethlycarbamoyl chloric
-15.11 Azathioprine
-14.75 Dibromochloropropane
-14.13 Nickel
-14.05 Benzidine
-13.85 Hycanthone methanesulfon
-13.48 Acetaldehyde
-13.22 Ethylene dibromide
-12.81 Diethyl sulfate
-12.43 Tris(2,3-dibromopropyl)P(
-12.11 Propylene oxide
-11.92 Arsenic(III)
-11.32 Hydrazine
-10.68 Styrene oxide
-9.74 2-Naphthylamine
-8.89 Benzo(a)pyrene
-8.72 Formaldehyde
-8.58 Myleran
-8.39 Vincristine sulfate
-7.15 Epichlorohydrin
-6.67 Uracil mustard
-5.90 Cyclophosphamide
-5.83 6-Mercaptopurine
-5.06 Ethylene oxide
-4.68 Dimethyl sulfide
-4.30 1-(2-Chloroethyl)-3-cycloh
-4.17 Chlorambucil
-3.85 Bleomycin
-3.67 Vinblastine sulfate
-3.31 Chloroprene
-3.29 MNNG
-2.34 Methyl bromide
-1.45 Chromium(IV)
-1.28 BCNU
-1.15 8-Methoxypsoralen (+UV]
-0.51 Melphalan
-0.31 ActinomycinD
-0.26 Cisplaten
AflatoxinB1
Thiotepa
Nitrogen mustard
Adriamycin
Triaziquone
oftest results. Forexample, the process ofaveraging testand class
scores was seriously questions because of the concern that a
single, possiblyhighly relevant, testresultwouldbedilutedby
largernumbersofnegativeresults. Thispotentialproblem was
emphasizedbecauseofanotherlimitationexpressedandthatwas
thatinputofdatadoesnotrequirepriorexpertreview,thusaposi-
tiveresultfromawell-performedtestmaybemaskedby several
studies notproperlyperformedwithnegativeresults. There was
less concern that the converse ofthis situation might occur.
Another concernexpressedbycommitteemembers aswell as
commissionmembersreviewingtheapproach wasthedecision
togiveequalweighttoin vitroandin vivotests. Invivodata are
generally viewed as morerelevant tohazard identification and
typically given more weight.
Score
0.20
0.54
0.58
0.76
0.79
1.38
1.46
1.74
2.11
2.44
2.73
3.14
3.29
3.34
3.36
3.58
4.87
4.89
5.71
5.78
5.88
5.95
6.05
6.60
7.11
7.77
7.80
8.04
8.30
8.49
9.11
9.52
9.74
9.96
10.42
10.60
11.09
11.30
12.32
12.78
13.92
14.17
14.55
16.90
18.19
18.32
18.32
18.33
19.01
19.48
19.81
23.07
23.10
23.31
24.67
25.91
26.70
29.22
49.67
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Many individualsreviewingtheprocessquestionedtheration-
aleformergingdatabysimpleaveragingofmodifiedscores. This
notonlyraisedthepotentialofdilutinguniquetestresponsesas
indicated earlier but was also ofconcern because there was a
general beliefthat tests measuring differentgenetic endpoints
(genemutation, aberrations, sisterchromatidexchange, tansfor-
mation, etc.)measurequitedifferentmechanisticphenomenathat
cannotbemergedbysimpleaveraging.Therewereotherconcerns
ofalessernaturethatwereidentifiedandrecognizedbythecom-
mittee during its deliberations overthepastseveral years.
Thecommittee membersconsideredalloftheseconcernsand
otherlikelylimitationsduringtheconstructionoftheMAPscor-
ing system. Resolutionofallquestions wasnotpossible, butthe
outputofthescoring systemwiththeexistingdatasuggestedin
severalcasesthatthepotentiallimitationsdidnotseriouslyflaw
theevaluation scheme.
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Results
Evenwiththelimitationsencountered, theMAPsystem pro-
ducedbyICPEMC appears toaccomplish manyofthegoalsin-
itially stated by the committee. Table 2 is a listing ofthe rank
order 113chemicalsusedinconstructing thedatabase. Somead-
ditional fine tuning ofthe system is expected, andbefore final
releasetherecouldbe someminorchanges intherankorderof
agents. In this latest version, ethanol, with an agent score of
-27.70 (Fig. 4), was the least genetically active agent in the
database, and triaziquone (Trenimon) with an agent score of
+49.67 (Fig. 5), wasthemostgenetically active. Therankorder,
with afew exceptions, seemsconsistentwith an intuitive rank-
ingofmutagenicactivity orwithrankingsfromotherexperts or
expert systems.
Thenumberoftestentries perchemical rangedfrom alowof
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FIGURE 5. The ICPEMC mutagenic activity profilefortriaziquone.
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FIGURE 4. TheICPEMCmutagenicactivityprofile forethanol.ASSEMBLYAND INTERPRETATION OF SHORT-TERM TESTDATA
6 studies for mestranol to 275 studies for cyclophosphamide.
Amongthe 113 data sets, 108 (96%)hadmixedtestresults (both
positiveandnegative). Fromthedataavailable atthetimeofthis
report, only C.I. acid red (11 entries), melamine (8 entries),
mestranol (6entries), andpolybrominatedbiphenyls (13entries)
consisted of entirely negative test data. Only chloroethyl-
cyclohexyl-nitrosourea (9 entries) had allpositive test results.
Data Interpretation
Tofully usetheMAPsystem, apracticalapplicationofagent
(Sa) scores must be developed. One can define, on a limited
basis, theactivityofachemical (e.g., mutagen, clastogen) from
theunequivocal, reproducibledatafrom asingletestsystemsuch
astheAmestest, theDrosophilasex-linkedrecessivelethal as-
say, orthe mousemicronucleus assay; however, such adefinition
Table3 Agent scoresforchemicalsreportedtobe
carcinogenic tohumans.
Chemical Agent score
Asbestos -8.39
Benzene -7.15
Vinyl chloride + 0.20
Diethylstilbestrol + 0.76
Azathioprine + 4.89
Benzidine + 5.88
Arsenic + 8.04
2-Naphthylamine + 9.11
Myleran + 9.96
Cyclophosphamide +11.30
Chlorambucil + 14.55
Chromium(VI) +19.01
8-Methoxypsoralen (+UVR) +19.81
Melphalan +23.07
Nitrogen mustard +26.70
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FIGURE 6. The ICPEMC mutagenic activity profile for isonaizide.
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FIGURE 7. TheICPEMCmutagenicactivityprofile for asbestos.D. BRUSICK
carrieslittleinformationconcerninghowgeneralizedtheactivity
mightbe acrossother testmethods orother speciesandhas no
quantitative indicationofpotency. TheICPEMC scoring system
attempts tointroducethese twoattributes intothemutagenicity
definition. Several usesfortheagent scorehavebeenconsidered
as discussedbelow.
The agent scorecouldbeviewed as anindicationofthelevel
of confidence (probability) that a chemical is a "general"
mutagen acrosstestandspeciesboundaries. Inotherwords,how
likelyisthechemical toproduce apositive ornegative response
in the next assay to whichitis subjected? Thehigherthe agent
score, thegreatertheprobabilitythatthechemicalis a"general"
mutagenandrepresents ahumanhazard. Agentsthatshow po-
tentbuthighlytest-method-specific responses(i.e., asingletest
positive)will notgenerate ahighagent score. Consequently, the
agent score from a test battery could serve as a quantitative
estimate ofthegenetic hazard ofacompound.
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FIGURE 8. TheICPEMC mutagenic activity profile forbenzene.
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FIGURE 9. TheICPEMC mutagenic activity profile for chloroform.
The agent score might be used in a qualitative manner to
establish potential for germ cell hazard. Among the 113
chemicals inthedatabase, 8 havebeen reportedpositive in ro-
dent tests forheritable germcell effects (14,15). Seven ofthe 8
(88%) germcellmutagensshowedpositiveagent scores. The one
compounddesignated a germcell mutagenwhichhad anegative
agent score was isoniazid (Fig. 6). A weakpositive effect was
reported inthe mouse heritabletranslocation assay (1).
Someconsiderationhasalsobeengivento the useoftheagent
score as anindicatorofcarcinogenicpotential. Fifteenofthe 113
chemicals fall into the IARC group Ihuman carcinogens (16).
Thirteen ofthe 15 (87%) havepositive agent scores (Table 3).
The two human carcinogens with negative agent scores are
asbestos(Fig. 7)andbenzene(Fig. 8). Attempts to usetheagents
score rankings to predict rodent carcinogenesis potency have
resulted in several conflicts with conventionaljudgments. Al-
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FIGURE 10. TheICPEMC mutagenic activity profile foramitrole.
though many rdent carcinogens fall among the chemicals with
high agent scores, some highly active rodent carciogens such
as chloroform (Fig. 9), amitrole (Fig. 10), and TCDD
(Fig. 11) all exhibited low agent scores. These agents belong
to a heterogenous group of chemicals whose mechanisms of
carcinogenesis are believed to be other than genotoxic (17). A
subset ofthe 113 chemicals with these characteristics is listed
in Table 4. Seventeen of the 19 agents in this nongenotoxic
category have negative agent scores consistent with their
assumed mechanisms and are also not mutagenic in the con-
ventional Ames assay.
Thecommittee iscurrently evaluating thealternative usesof
the agent scores. The relative ranking ofchemicals in Table 2
coincides reasonably well with anintuitive assessment oftheir
genetic hazard. This isespecially true forthosewith veryhigh
or very low agent scores. There appear to be a few anomalies
amongthechemicals inthedatabase, forexample, procarbazine.
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FIGuRE 11. TheICPEMC mutagenicactivity profile forTUDD.
blce4 Agentscoresforhem ka to prduce tumors in rodents
by no c mechanisms.
Chemical Agent score
Diethylhexylphthalate -17.35
PCBs -16.88
Ethylenethiourea -16.77
PBBs -15.46
Chloroform -15.28
1,1,l-Tnchloroethane -14.05
Tetrachloroethylene -13.48
Phenobarbital -13.22
Endrin -12.81
Progesterone -12.11
Amitrole -10.68
Asbestos -8.39
Heptachlor -5.06
DDT -4.30
Carbontetrachloride -4.17
Dieldrin -3.67
Trichloroethylene -2.34
Diethylstilbestrol +0.76
TCDD +1.38
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FIGURE 12. TheICPEMC mutagenicactivityprofile forprocarbazine.
Hydrochloric acid (Fig. 12) has arelatively low agent score of
3.36. This chemical is highly mutagenic in rodent germ cells
(18), yet ranks lower thanotheragents that wouldpresumably
poselessofageneticrisk(e.g.,acetaldehyde, nickelandformal-
dehyde). Benzene, whichisquiteactiveasaclastogeninvivo, has
anagent scoreof-7.15. 'Ibisanomalyappearstoresultfromthe
factthatalargenumberofnegativestudieshavebeenconducted
in vitro and these have diluted the limited number ofpositive
resultsin vivo. Thisis anexamplerelatedto someoftheconcerns
expressedearlier. Bothprocarbazineandbenzeneappearlower
in the agent scorerankings thanmightbepresumedgenerally.
Few instanccs of this situation were found upon an extensive
analysis ofthiedatabase.
Conclusions
Inspite oftheearly stage ofdevelopment, it is clear thatthe
ICPEMC committee I MAP avvroach ofintegzratingz and vro-
cessinggenetictoxicologydataiscapableofmeetingmanyofthe
initialrequirements setforthbythecommittee. Theapproachis
abletocopewithredundant, disparate, andmissingdata inthe
published literature.
From the current database of 113 chemicals, the scoring
method in its current configuration was capable of correctly
assigningscorestoalmostalloftheknownheritablemutagens.
Mosthumancarcinogensinthedatabasewereassignedpositive
agentscores, andthecategory ofrodentcarcinogenspresumed
toinducetumorsbynongenotoxicmechanisms wereallassign-
ed negative agent scores by the method.
A crucial element inthis exercise was to compare the muta-
genic ranking of chemicals with their ranking as rodent car-
cinogens. Toaccomplishthis, aparallel systemforrank-ordering
rodent carcinogens was developed by Nesnow (19). Once this
newdatabaseisfilledwithsufficientchemicals tomakeacom-
parisonmeaningful, theresults will bepublished.
Acomprehensive statisticalanalysishasbeenperformedwith
the existing database (11). Several preliminary findings have
producedimportantinsightintomutagenicity testing: a)In vitro
andin vivotestsappeartorespondsimilarly toabroadrangeof
chemicals. b)Chemicalsdonotappeartobehighlyspecific for
genetic endpoints (gene mutation, sister chromatid exchange,
clastogenicity, cell transformation). Class scores proved to be
very congruent with the consensus (Sa) scores for the 113
chemicals. c) Using the 113 chemicals as surrogates for the
universeofchemicals, therangeofagentscoresfallgenerally on
acontinuous, rather thanabimodal, scale with approximately
halfthechemicals havingpositive agent scoresandhalfhaving
negative agent scores.
ThestudyandrefinementoftheICPEMCcommittee 1 MAP
methodofcomplexmutagenicitydataevaluationwillcontinue.
Its adaptation to data assessment will be enhanced by the
availabilityofsoftwaremodifiedforuseonpersonalcomputers.
Basedontheinitialexperienceswiththeapproach, itisclearthat
important insights about genetic tests and test batteries will
emerge. Whetherthis approach willbreakthrough thecurrent
barriers encountered in using genetic test to predict car-
cinogenicity remains tobe seen.
The authorrecognizes ICPEMC for its support oftheCommittee's workon
this project. Other ICPEMC committee 1 members are Paul Lohman, Mort
Mendelsohn, MikeWaters, andJohnAshby. Additional statisticalandprogram-
ming assistance has beenprovided by Dan Moore, II andWalter Lohman.
REFERENCES
1. ICPEMC, Committee 1 FinalReport. Screening strategy forchemicalsthat
arepotentialgerm-cell mutagensinmammals. Mutat. Res. 114: 117-177(1983).
2. Brusick, D. Unifiedscoring systemandactivity definitions forresults from
in vitro and sub-mammalian mutagenesis test batteries. In: Health Risk
Analysis (E. D. Copanhaven, C. R. Richmond, and P. J. Walsh, Ed.),
Franklin Institute Press, Philadelphia, 1981, pp. 273-286.
3. Squire, R. A. Rankinganimalcarcinogens: aproposedregulatoryapproach.
Science 214: 877-880 (1981).
4. Waters, M. D., Stack, H. F., Brady, A. L., Lohman, P. H. M., Vanio, H. Use
ofcomputerizeddatalistingsandactivityprofilesofgenetic andrelated ef-
fects in thereview of 195compounds. Mutat. Res. 205: 295-312 (1988).
5. Benigni, R., and Giuliani, A. Predicting carcinogenicity with short-term
tests: biological models and operational approaches. Mutat. Res. 205:
227-236 (1988).
6. Chankong, V., Haimes, Y. Y., Rosenkranz, H. S., andPet-Edwards, J. The
carcinogenicity predictionandbattery selection (CPBS) method: aBayesian
approach. Mutat. Res. 153: 135-166 (1985).ASSEMBLYAND INTERPRETATION OF SHORT-TERM TESTDATA 111
7. Parodi, S., Taningher, M., Romano, P., Grilli, S., andSanit, L. Mutagenic
andcarcinogenicpotencyindicesandtheircorrelation. Teratog. Carcinog.
Mutagen. 10: 177-197 (1990).
8. Gold, L. S., Sawyer, C. B., Magaw, R., Backman, G. M.,deVeciana, M.,
Levinson, R., Hooper, N. K., Havender, W R., Berstein, L., Peto, R., Pike,
M. C., and Ames, B. N. A Carcinogenic Pbtency Database ofthe stand-
ardized results ofanimal bioassays. Environ. Health Perspect. 58: 9-319
(1984).
9. Nesnow, S. Amulti-factor carcinogenpotency ranking scaleforcomparing
the activityofchemicals. Mutat. Res. 239: 83-115 (1990).
10. Lohman, P. H. M., Mendelsohn, M. L., Moor, D. H., II, Waters, M. D.,
Brusick, D. J., Ashby, J., andLohman, W. Amethodforcomparing, com-
biningandinterpretingshort-term genotoxicitydata: thebasic system. Mutat.
Res., submitted.
11. Moore, D. H., H, Mendelsohn, M. L., andLohman, P. H. M. Amethodfor
comparing, combiningandinterpretingshort-termgenotoxicitydata: theop-
timal useofdose information. Mutat. Res., submitted.
12. Mendelsohn, M. L., Moore, D. H., II, andLohman, P. H. M. Amethodfor
comparing, combiningandinterpreting short-termgenotoxicity data: results
and interpretation. Mutat. Res., submitted.
13. IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to
Humans, Supplement 6, Genetic and Related Effects: An Updating of
SelectedIARC MonographsfromVolumes 1-42. International Agency for
Research onCancer, Lyon, 1987.
14. Russell, L. B., Selby, P. B., VbnHalle, E., Sheridan, W., andValcovic, L.
Themousespecific-locustestwithagentsotherthanradiations. Interpretation
ofdata and recommendations for future work. Mutat. Res. 86: 329-354
(1981).
15. Ehling, U. H. Quantitationofthegeneticriskofenvironmental chemicals.
Risk Anal. 8: 45-57 (1988).
16. IARC. Chemicals and Industrial Processes Associated with Cancer in
Humans, Supplement 1, Volumes 1-20. International Agency forResearch
on Cancer, Lyon, 1979.
17. Williams, G. M., andWisberger, J. H. Chemicalcarinogens. In: TheBasic
ScienceofPbisons, 3rded. (C. Klaassen, Ed.), Macmillan, Inc., NewYork,
1986, pp. 99-173.
18. Ehling, U. H.,andNeuhauser, A. Procarbazine-inducedspecific-locus muta-
tions in mice. Mutat. Res. 59: 245-256 (1979).